Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Other beta-D-glucosides refers to a broad chemical classification of compounds where a glucose molecule is linked to another functional group (an aglycone) via a beta-glycosidic bond (PubChem). This term does not represent a specific biological macromolecule such as a receptor or enzyme; instead, it describes a class of substrates typically processed by glycoside hydrolases, most notably beta-glucosidases (EC 3.2.1.21) (PubMed: 15544331). In human physiology, the metabolism of specific beta-D-glucosides like glucosylceramide is critical, and its failure due to deficiencies in enzymes like acid beta-glucosidase (GBA1) leads to lysosomal storage disorders such as Gaucher disease (NIH: Genetic and Rare Diseases Information Center). While these glucosides are central to the pathology of certain metabolic diseases, they are not themselves therapeutic targets; rather, the enzymes that synthesize or degrade them are the focus of pharmacological interventions like enzyme replacement therapy and substrate reduction therapy. Consequently, this entry is considered incorrect as a therapeutic target and instead represents a category of metabolic intermediates.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other beta-D-glucoside.